By Professor Elgene Lim

Conference Abstracts

Tran M; Saw K; Mo J; Carson E-K; MacDonald K; Lloyd M; Rossiter G; Crawford M; Mazariego C; Dadich A; Brydon P; River J; Dear RF-G; Lim E; Lin FP-Y, 2026, 'Patient preference for large language model (LLM)–optimised oncology trial information: A randomised controlled crossover study.', in Journal of Clinical Oncology, American Society of Clinical Oncology (ASCO), Vol. 44, pp. 6 - 6, http://dx.doi.org/10.1200/jco.2026.44.19_suppl.6

Lobanov AV; Kim HJ; Kanwal S; Harvey K; Reeves J; Batten M; Kiedik B; Roden DL; Hui MN; Stewart KP; Hofmann O; O’Toole S; Lim E; Grimmond SM; Swarbrick A; Perou CM, 2026, 'Abstract 44: scSubtype2.0: Predictor of breast cancer molecular subtypes at single cell resolution.', in Cancer Research, American Association for Cancer Research (AACR), Vol. 86, pp. 44 - 44, http://dx.doi.org/10.1158/1538-7445.am2026-44

Kim HJ; Kiedik B; Harvey K; Kanwal S; Douglas J; Reeves J; Lobanov A; Roden DL; Van Der Leij S; Hui MN; Al’Khafaji A; Lim E; Grimmond SM; Lundeberg J; Perou CM; Swarbrick A, 2026, 'Abstract 7282: A comprehensive multiomics atlas of treatment-naïve breast cancer uncovers co-occurring tumor-immune ecosystems driving immune hot and cold phenotypes', in Cancer Research, American Association for Cancer Research (AACR), Vol. 86, pp. 7282 - 7282, http://dx.doi.org/10.1158/1538-7445.am2026-7282

Jhaveri K; Neven P; Casalnuovo ML; Kim S-B; Tokunaga E; Aftimos P; Saura C; O’Shaughnessy J; Harbeck N; Carey LA; Curigliano G; Llombart-Cussac A; Lim E; Luz García Tinoco MDL; Sohn J; Mattar A; Zhang Q; Huang C-S; Hung C-C; Martinez Rodriguez JL; Borrego MR; Nakamura R; Pradhan KR; Cramer von Laue C; Barrett E; Cao S; Wang XA; Smyth LM; Bidard F-C, 2025, 'Abstract GS1-01: Imlunestrant, an Oral Selective Estrogen Receptor Degrader (SERD), as Monotherapy & Combined with Abemaciclib, for Patients with ER+, HER2- Advanced Breast Cancer (ABC), Pretreated with Endocrine Therapy (ET): Results of the Phase 3 EMBER-3 trial', in Clinical Cancer Research, American Association for Cancer Research (AACR), Vol. 31, pp. gs1-01-gs1-01, http://dx.doi.org/10.1158/1557-3265.sabcs24-gs1-01

Kiedik B; Roden DL; Harvey K; Al-Eryani G; Wu SZ; Hui MN; O’Toole S; Lim E; Perou CM; Swarbrick A, 2025, 'Abstract P4-09-19: Exploring cellular heterogeneity of localised breast cancers', in Clinical Cancer Research, American Association for Cancer Research (AACR), Vol. 31, pp. p4-09-19-p4-09-19, http://dx.doi.org/10.1158/1557-3265.sabcs24-p4-09-19

Jhaveri K; Nakajima TE; Giordano A; Juric D; Ma C; Unni N; Goetz MP; Kitano S; Loi S; Rugo H; Bidard F-C; Saura C; Lim E; Neven P; O’Shaughnessy J; Bhave M; Tan TJ; Bedard PL; Vanacker H; O’Regan R; Turner NC; Cortes J; Chia S; Campone M; Chau V; Hanley MP; Du L; Lombard A; Ramstetter M; Estrem S; Meric-Bernstam F, 2025, 'Abstract PS7-03: A first-in-human phase 1a/b trial of LOXO-783, a potent, highly mutant-selective, brain-penetrant, allosteric PI3Kα H1047R inhibitor in PIK3CA H1047R-mutant advanced breast cancer and other solid tumors: Results from the PIKASSO-01 study', in Clinical Cancer Research, American Association for Cancer Research (AACR), Vol. 31, pp. ps7-03-ps7-03, http://dx.doi.org/10.1158/1557-3265.sabcs24-ps7-03

Howard FM; Fasching PA; Santa-Maria CA; Lim E; Sparano J; Lustberg M; Bachelot T; Blyuss O; Brezden-Masley C; Park YH; Akdere M; Ye F; Pantoja K; Castro PD; Kurz C; Razavi P, 2025, '372P A NATALEE data–based machine learning (ML) model to predict distant recurrence (DR) and treatment (tx) effect in real-world (RW) patients (pts) with HR+/HER2– early breast cancer (EBC) without CDK4/6 inhibitor (CDK4/6i) tx', in Annals of Oncology, Elsevier, Vol. 36, pp. s358, http://dx.doi.org/10.1016/j.annonc.2025.08.797

Fasching PA; Barrios CH; Lim E; Graff SL; Chia S; Frenel J-S; Im S-A; Huang C-S; Ring A; Nowecki Z; Liu Q; Akdere M; Zarate JP; Hu H; Pantoja K; O'Shaughnessy JA, 2025, 'P001: Prognostic variables for risk of recurrence in patients (pts) with HR+/HER2–early breast cancer (EBC) using data from the NATALEE trial: a machine learning (ML) model–based analysis', in The Breast, Elsevier, Vol. 80, pp. 103895, http://dx.doi.org/10.1016/j.breast.2025.103895

Kiedik B; Roden D; Harvey K; Al-Eryani G; Wu S; Hui M; O'Toole S; Lim E; Perou C; Swarbrick A, 2024, 'Abstract PO5-01-09: Exploring cellular heterogeneity of localised breast cancers', in Cancer Research, American Association for Cancer Research (AACR), Vol. 84, pp. po5-01-09-po5-01-09, http://dx.doi.org/10.1158/1538-7445.sabcs23-po5-01-09

Freelander A; Laven-Law G; Eshraghi L; Geetha N; Somerville P; Pickering M; Alexandrou S; Caldon CE; Tilley WD; Hickey TE; Lim E, 2022, 'Selective Androgen Receptor Modulators in combination with CDK4/6 inhibitors demonstrate anti-cancer activity in preclinical treatment resistant ER plus AR plus breast cancer models', in CANCER RESEARCH, AMER ASSOC CANCER RESEARCH, TX, San Antonio, Vol. 83, presented at San Antonio Breast Cancer Symposium, TX, San Antonio, 06 December 2022 - 10 December 2022, http://dx.doi.org/10.1158/1538-7445.SABCS22-P4-08-16

Wong K; Sheehan-Dare G; Nguyen A; Ho B; Liu V; Lee J; Brown LJ; Dear RF-G; Chan L; Pathmanandavel S; Sharma S; Malaroda A; Smith I; Lim E; Emmett L, 2022, '⁶⁴Cu-SAR-Bombesin PET-CT imaging in the staging of ER+/PR+/HER2-metastatic breast cancer: Safety, dosimetry, and feasibility in a phase I trial.', in JOURNAL OF CLINICAL ONCOLOGY, LIPPINCOTT WILLIAMS & WILKINS, ELECTR NETWORK, Vol. 40, presented at Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), ELECTR NETWORK, 03 June 2022 - 07 June 2022

Wong K; Sheehan-Dare G; Nguyen A; Ho B; Liu V; Lee J; Brown LJ; Dear RF-G; Chan L; Pathmanandavel S; Sharma S; Malaroda A; Smith I; Lim E; Emmett L, 2022, '⁶⁴Cu-SAR-Bombesin PET-CT imaging in the staging of ER+/PR+/HER2- metastatic breast cancer: Safety, dosimetry, and feasibility in a phase I trial.', in Journal of Clinical Oncology, American Society of Clinical Oncology (ASCO), Vol. 40, pp. 3092 - 3092, http://dx.doi.org/10.1200/jco.2022.40.16_suppl.3092

Jhaveri KL; Jeselsohn R; Lim E; Hamilton EP; Yonemori K; Beck JT; Kaufman PA; Sammons S; Bhave MA; Saura C; Calvo E; Meniawy T; Larson T; X. C; García-Corbacho J; Cao S; Estrem ST; Milata JL; Nguyen B; Beeram M, 2022, 'A phase 1a/b trial of imlunestrant (LY3484356), an oral selective estrogen receptor degrader (SERD) in ER-positive (ER+) advanced breast cancer (aBC) and endometrial endometrioid cancer (EEC): Monotherapy results from EMBER.', in Journal of Clinical Oncology, American Society of Clinical Oncology (ASCO), Vol. 40, pp. 1021 - 1021, http://dx.doi.org/10.1200/jco.2022.40.16_suppl.1021

Lim E; Brufsky A; Rugo HS; Vogel CL; O'Shaughnessy J; Getzenberg RH; Barnette KG; Rodriguez D; Bird G; Steiner MS; Linden HM, 2022, 'Phase 3 ENABLAR-2 study to evaluate enobosarm and abemaciclib combination compared to estrogen-blocking agent for the second-line treatment of AR+, ER+, HER2- metastatic breast cancer in patients who previously received palbociclib and estrogen-blocking agent combination therapy.', in Journal of Clinical Oncology, American Society of Clinical Oncology (ASCO), Vol. 40, pp. tps1121 - tps1121, http://dx.doi.org/10.1200/jco.2022.40.16_suppl.tps1121

Freelander A; Laven-Law G; Eshraghi L; Chia KM; Pickering M; Yong A; Wilkinson A; Alexandrou S; Caldon CE; Hickey TE; Tilley WD; Lim E, 2022, 'Abstract PD2-02: Combination CDK4/6 inhibition and AR agonism suppresses the growth of CDK4/6 inhibitor resistant breast cancers', in Cancer Research, American Association for Cancer Research (AACR), Vol. 82, pp. pd2-02-pd2-02, http://dx.doi.org/10.1158/1538-7445.sabcs21-pd2-02

Brown LJ; Meredith T; Yu J; Patel A; Neal B; Arnott C; Lim E, 2021, 'Heart failure therapies for the prevention of HER2-monoclonal antibody-mediated cardiotoxicity: A systematic review and meta-analysis', in ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, WILEY, Vol. 17, pp. 119 - 119, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000717281500164&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Wong V; De Boer R; Baron-Hay S; Blum R; Forster B; Chua S; Clarke K; Cuff K; Green M; Lim E; Mok K; Nott LW; Nottage M; Tafreshi A; Tsoi D; Uccelini A; Gibbs P; Lok SW, 2021, 'Patient-reported outcomes of medicine access programmes: A sub-study of KARMA (Kisqali Access Registry for Metastatic Breast Cancer in Australia)', in ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, WILEY, Vol. 17, pp. 175 - 176, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000717281500285&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Moore HM; Boni V; Bellet M; De Las Heras BB; Cortés MG; Oakman C; Schmid P; Trinh XB; Wheatley D; Jhaveri KL; Kabos P; Lim E; Velu T; Metcalfe C; Gates MR; Chang C-W; Bond J; Goldstein LD; Lauchle JO; Bardia A, 2021, 'Evaluation of pharmacodynamic (PD) and biologic activity in a preoperative window-of-opportunity (WOO) study of giredestrant (GDC-9545) in postmenopausal patients (pts) with estrogen receptor-positive, HER2-negative (ER+/HER2–) operable breast cancer (BC).', in Journal of Clinical Oncology, American Society of Clinical Oncology (ASCO), Vol. 39, pp. 577 - 577, http://dx.doi.org/10.1200/jco.2021.39.15_suppl.577

Sheehan-Dare G; Lim E; Koo CM; Chan L; Lau B; Dear R; Ho B; Sharma S; Hickey A; Malaroda A; Smith I; Nguyen A; Parker M; Emmett L, 2021, 'Preliminary assessment of the diagnostic value of Cu-64-SAR-Bombesin PET-CT imaging for staging of ER+/PR+HER2-metastatic breast cancer disease: comparison with conventional imaging', in JOURNAL OF NUCLEAR MEDICINE, SOC NUCLEAR MEDICINE INC, Vol. 62, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000713713600278&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Wu SZ; Roden D; Al Eryani G; Junankar S; Lim E; Thennavan A; Andersson A; Williams S; Gong J; Fropf R; Fuhrman K; Lundeberg J; Perou C; Swarbrick A, 2021, 'An integrated multi-omic cellular atlas of human breast cancers.', in CANCER RESEARCH, AMER ASSOC CANCER RESEARCH, PA, Philadelphia, Vol. 81, presented at Annual Meeting of the American-Association-for-Cancer-Research (AACR), PA, Philadelphia, 10 April 2021 - 21 May 2021

Palmieri C; Linden H; Birrell S; Lim E; Schwartzberg LS; Rugo HS; Cobb P; Jain K; Vogel C; O'Shaughnessy J; Johnston SRD; Getzenberg RH; Barnette KG; Steiner M; Brufsky AM; Overmoyer B, 2021, '100P Efficacy of enobosarm, a selective androgen receptor (AR) targeting agent, in patients with metastatic AR+/ER+ breast cancer resistant to estrogen receptor targeted agents and CDK 4/6 inhibitor in a phase II clinical study', in Annals of Oncology, Elsevier, Vol. 32, pp. s66, http://dx.doi.org/10.1016/j.annonc.2021.03.114

Yap Y-S; Kim S-B; Chiu JWY; Lim E; Broom R; Liu Z; Sagara Y; Chao T-Y; Sherwood S; McNaughton RE; Wei RJ; Toi M, 2021, '48P Abemaciclib combined with adjuvant endocrine therapy in patients from Asia with high risk early breast cancer: monarchE', in Annals of Oncology, Elsevier, Vol. 32, pp. s41 - s42, http://dx.doi.org/10.1016/j.annonc.2021.03.062

Palmieri C; Linden H; Birrell S; Lim E; Schwartzberg LS; Rugo HS; Cobb P; Jain K; Vogel C; O'Shaughnessy JA; Getzenberg RH; Steiner MS; Brufsky A; Overmoyer B, 2020, 'Efficacy and safety of enobosarm, a selective androgen receptor modulator, to target AR in women with advanced ER plus /AR plus breast cancer - final results from an international Phase 2 randomized study', in CANCER RESEARCH, AMER ASSOC CANCER RESEARCH, ELECTR NETWORK, Vol. 81, presented at San Antonio Breast Cancer Virtual Symposium, ELECTR NETWORK, 08 December 2020 - 11 December 2020

Lim E; Beeram M; Prawira A; Patnaik A; Wang XA; Young SRL; Smyth LM; Hamilton EP, 2020, 'EMBER: A phase 1a/b trial of LY3484356, a novel, oral selective estrogen-receptor degrader (SERD), in advanced ER plus breast cancer and endometroid endometrial cancer', in CANCER RESEARCH, AMER ASSOC CANCER RESEARCH, ELECTR NETWORK, Vol. 81, presented at San Antonio Breast Cancer Virtual Symposium, ELECTR NETWORK, 08 December 2020 - 11 December 2020

Portman N; Milioli H; Alexandrou S; Coulson R; Yong A; Fernandez K; Chia K; Halilovic E; Segara D; Parker A; Haupt S; Haupt Y; Tilley W; Swarbrick A; Caldon L; Lim E, 2020, 'Mdm2 inhibition synergises with endocrine therapy or cdk4/6 inhibition for the treatment of estrogen receptor-positive breast cancer', in CANCER RESEARCH, AMER ASSOC CANCER RESEARCH, ELECTR NETWORK, Vol. 81, presented at San Antonio Breast Cancer Virtual Symposium, ELECTR NETWORK, 08 December 2020 - 11 December 2020

Lim E, 2020, 'A phase Ib study to evaluate the oral selective estrogen receptor degrader GDC-9545 alone or combined with palbociclib in metastatic ER-positive HER2-negative breast cancer.', in Journal of Clinical Oncology, American Society of Clinical Oncology, Chicago, presented at American Society of Clinical Oncology, Chicago, 29 May 2020 - 31 May 2020

Lok SW; Baron-Hay S; Lim E; Blum R; Boyle F; Clarke K; Cuff K; Green M; Malik L; Mok K; Murray N; Nott L; Nottage M; Tafreshi A; Tsoi D; Yeo B; Gibbs P; De Boer R, 2020, 'Abstract OT2-02-01: A 'real world' experience of CDK4/6 inhibition with ribociclib and endocrine therapy in hormone receptor positive metastatic breast cancer in Australia', in Cancer Research, American Association for Cancer Research (AACR), Vol. 80, pp. ot2-02-01-ot2-02-01, http://dx.doi.org/10.1158/1538-7445.sabcs19-ot2-02-01

Lim E; Boyle F; Okera M; Loi S; Goksu SS; van Hal G; Hartman DG; Gable JC; Price GL; Hossain A; Gainford MC; Ezquerra MB, 2020, 'Abstract P5-14-05: The impact of food on tolerability of abemaciclib in patients with previously treated hormone receptor-positive, HER2-negative, metastatic breast cancer: An open-label, randomized phase 2 study', in Cancer Research, American Association for Cancer Research (AACR), Vol. 80, pp. p5-14-05-p5-14-05, http://dx.doi.org/10.1158/1538-7445.sabcs19-p5-14-05

Jhaveri K; Winer EP; Lim E; Fidalgo JA; Bellet M; Mayer IA; Boni V; Patel JM; Bardia A; Garcia JM; Kabos P; Gates M; Chen Y-C; Fredrickson J; Wang X; Friedman LS; Spoerke J; Gendreau S; Metcalfe C; Liu L; Chang C-W; Monemi S; Gonzalez M; McCurry U; Milan S; Humke EW; Loi S, 2020, 'Abstract PD7-05: A first-in-human phase I study to evaluate the oral selective estrogen receptor degrader (SERD), GDC-9545, in postmenopausal women with estrogen receptor-positive (ER+) HER2-negative (HER2-) metastatic breast cancer', in Cancer Research, American Association for Cancer Research (AACR), Vol. 80, pp. pd7-05-pd7-05, http://dx.doi.org/10.1158/1538-7445.sabcs19-pd7-05

Hickey T; Selth L; Chia KM; Milioli HH; Laven-Law G; Roden D; Jindal S; Hui M; Ebrahimie E; Birrel SN; Stello S; Iggo R; Alexandrou S; Caldon L; Finlay-Shultz J; Abdel-Fatah TM; Ellis IO; Zwart W; Palmieri C; Sartorious CA; Swarbrick A; Lim E; Carrol JS; Tilley WD, 2020, 'The androgen receptor is a tumour suppressor in estrogen receptor positive breast cancer', in Journal of the Endocrine Society, Oxford University Press (OUP), Vol. 4, pp. or05 - or06, presented at Endocrine Society Annual Meeting, http://dx.doi.org/10.1210/jendso/bvaa046.982

Wahlroos S; Wilkinson A; Milioli H; Portman N; Gallego-Ortega D; Lim E, 2019, 'Concurrent exercise and chemotherapy in preclinical breast cancer models', in CANCER RESEARCH, AMER ASSOC CANCER RESEARCH, TX, San Antonio, Vol. 80, presented at 42nd Annual San Antonio Breast Cancer Symposium, TX, San Antonio, 09 December 2019 - 14 December 2019, http://dx.doi.org/10.1158/1538-7445.SABCS19-P4-14-13

Lim E; Hickey TA; Selth LA; Chia KM; Milioli HH; Roden D; Laven-Law G; Jindal S; Hui M; Ebrahimie E; Birrell SN; Stelloo S; Caldon CE; Finlay-Schultz J; Abdel-Fatah TM; Ellis IO; Zwart W; Palmieri C; Sartorius CA; Swarbrick A; Carroll JS; Tilley WD, 2019, 'Abstract GS2-03: The androgen receptor is a tumour suppressor in estrogen receptor positive breast cancer', in Cancer Research, American Association for Cancer Research (AACR), TX, San Antonio, Vol. 80, pp. gs2-03-gs2-03, presented at 42nd Annual San Antonio Breast Cancer Symposium, TX, San Antonio, 09 December 2019 - 14 December 2019, http://dx.doi.org/10.1158/1538-7445.sabcs19-gs2-03

Chen J; Carson E; Segara D; Parker A; O'Toole S; Coates A; Mann B; Lindeman G; Tilley W; Lim E, 2019, 'The WinPro study: A window of opportunity study of endocrine therapy with and without prometrium in postmenopausal women with early stage hormone receptor-positive breast cancer', in Oncology Abstracts, Bioscientifica, http://dx.doi.org/10.1530/oncolabs.1.p011

Swarbrick A; Wu S; Roden D; Al-Eryani G; O'Toole S; Lim E, 2019, 'Abstract GS1-01: Landscape of the breast tumour microenvironment at single-cell resolution', in Cancer Research, American Association for Cancer Research (AACR), Vol. 79, pp. gs1-01-gs1-01, http://dx.doi.org/10.1158/1538-7445.sabcs18-gs1-01

Carson E; Segara D; Parker A; O'Toole S; Coates A; Mann B; Lindeman G; Tilley W; Lim E, 2019, 'Abstract OT1-01-03: The WinPro study: A window of opportunity study of endocrine therapy with and without prometrium in postmenopausal women with early stage hormone receptor-positive breast cancer', in Cancer Research, American Association for Cancer Research (AACR), Vol. 79, pp. ot1-01-03-ot1-01-03, http://dx.doi.org/10.1158/1538-7445.sabcs18-ot1-01-03

Metzger O; Mandrekar S; Loibl S; Mundhenke C; Seiler S; Valagussa P; Lim E; Tripathy D; Winer E; Huang C; Carey L; Francis P; Miller K; Goetz M; Prat A; Loi S; Krop I; Gianni L; Delalogue S; Vaz-Luis I; Dockter T; Lanzillotti J; Ciruelos E; DeMichele A, 2019, 'Abstract OT3-02-07: PATINA: A randomized, open label, phase III trial to evaluate the efficacy and safety of palbociclib + anti-HER2 therapy + endocrine therapy (ET) vs. anti-HER2 therapy + ET after induction treatment for hormone receptor positive (HR+)/HER2-positive metastatic breast cancer (MBC)', in Cancer Research, American Association for Cancer Research (AACR), Vol. 79, pp. ot3-02-07-ot3-02-07, http://dx.doi.org/10.1158/1538-7445.sabcs18-ot3-02-07

Swarbrick A; Cazet A; Hui M; O'Toole S; Lim E; Martin M, 2019, 'Abstract P5-07-03: Small molecule inhibition of smoothened in triple negative breast cancer-associated fibroblasts depletes cancer stem cells and sensitizes to cytotoxic chemotherapy in mice and humans', in Cancer Research, American Association for Cancer Research (AACR), Vol. 79, pp. p5-07-03-p5-07-03, http://dx.doi.org/10.1158/1538-7445.sabcs18-p5-07-03

Portman N; Milioli HH; Young A; Coulson R; Alexandrou S; Lam N; Haup S; Haup Y; Caldon L; Deng N; Lim E, 2019, 'Activation of p53 in combination with endocrine and CDK targeted therapies in ER+ breast cancer', in Oncolabs, Bioscientifica, presented at 7th PacRim Breast & Prostate Cancer Meeting, http://dx.doi.org/10.1530/oncolabs.1.P043

Milioli HH; Chia KM; Portman N; Young A; Laven-Law G; Selth L; Tilley WD; Hickey T; Lim E, 2019, 'Androgen receptor activation in Endocrine-Resistant ER-positive breast cancer', in Oncolabs, Bioscientifica, presented at 7th PacRim Breast & Prostate Cancer Meeting, http://dx.doi.org/10.1530/oncolabs.1.P034

Stirzaker C; Chia KM; Portman N; Milioli HH; Clifton S; Achinger-Kawecka J; Nair S; Lim E; Clark S, 2019, 'DNA demethylation agents as a therapeutic approach in endocrine-resistant breast cancer', in Oncolabs, presented at 7th PacRim Breast & Prostate Cancer Meeting, http://dx.doi.org/10.1530/oncolabs.1.P049

Alexandrou S; Milioli HH; Portman N; Lee C; Fernandez K; Blake D; Lim E; Caldon L, 2019, 'S phase dysregulation occurs following resistance to CDK4/6 inhibition ER+ breast cancer', in Oncolabs, Bioscientifica, presented at 7th PacRim Breast & Prostate Cancer Meeting, http://dx.doi.org/10.1530/oncolabs.1.P001

Chia KM; Milioli HH; Portman N; Laven-Law G; Coulson R; Young A; Segara D; Parker A; Caldon L; Deng N; Swarbrick A; Tilley W; Hickey T; Lim E, 2019, 'Targeting AR in endocrine-resistant breast cancer', in Oncolabs, Bioscientifica, presented at 7th PacRim Breast & Prostate Cancer Meeting, http://dx.doi.org/10.1530/oncolabs.1.P012

Chia KM; Milioli H; Portman N; Laven-Law G; Yong A; Swarbrick A; Caldon L; Tilley W; Hickey T; Lim E, 2018, 'Abstract P6-20-04: Activation of AR inhibits growth of endocrine-resistant breast cancer', in Cancer Research, American Association for Cancer Research (AACR), TX, San Antonio, Vol. 79, pp. p6-20-04-p6-20-04, presented at San Antonio Breast Cancer Symposium, TX, San Antonio, 04 December 2018 - 08 December 2018, http://dx.doi.org/10.1158/1538-7445.sabcs18-p6-20-04

Wahlroos S; Wilkinson A; Gallego-Ortega D; Febbraio M; Lim E, 2018, 'Concurrent exercise and chemotherapy in preclinical breast cancer models', in CANCER RESEARCH, AMER ASSOC CANCER RESEARCH, TX, San Antonio, Vol. 79, presented at San Antonio Breast Cancer Symposium, TX, San Antonio, 04 December 2018 - 08 December 2018, http://dx.doi.org/10.1158/1538-7445.SABCS18-P6-21-05

Lim E; Carson E, 2018, 'The WinPro study: A window of opportunity study of endocrine therapy with and without prometrium in postmenopausal women with early stage hormone receptor-positive breast cancer', in Asia-Pacific Journal of Clinical Oncology, Wiley, Perth Convention and Exhibition Centre, Perth, Western Australia, Vol. 14, pp. 194 - 195, presented at COSA's 45th Annual Scientific Meeting, Perth Convention and Exhibition Centre, Perth, Western Australia, 13 November 2018 - 15 November 2018, http://dx.doi.org/10.1111/ajco.13089

Loibl S; Metzger O; Mandrekar SJ; Mundhenke C; Seiler S; Valagussa P; DeMichele A; Lim E; Tripathy D; Winer EP; Huang C; Carey L; Francis P; Miller KD; Goetz MP; Prat A; Loi S; Krop I; Gianni L; Ciruelos EM, 2018, 'PATINA: A randomized, open label, phase III trial to evaluate the efficacy and safety of palbociclib + Anti-HER2+therapy plus endocrine therapy (ET) vs. anti-HER2 therapy + ET after induction treatment for hormone receptor positive (HR1)/HER2-positive metastatic breast cancer (MBC)', in ANNALS OF ONCOLOGY, OXFORD UNIV PRESS, GERMANY, Munich, Vol. 29, pp. 121 - 121, presented at 43rd ESMO Congress (ESMO), GERMANY, Munich, 19 October 2018 - 23 October 2018

Loibl S; Metzger O; Mandrekar SJ; Mundhenke C; Seiler S; Valagussa P; DeMichele A; Lim E; Tripathy D; Winer EP; Huang C; Carey L; Francis P; Miller KD; Goetz MP; Prat A; Loi S; Krop I; Gianni L; Ciruelos EM, 2018, 'PATINA: A randomized, open label, phase III trial to evaluate the efficacy and safety of palbociclib + Anti-HER2 therapy + endocrine therapy (ET) vs. anti-HER2 therapy + ET after induction treatment for hormone receptor positive (HR+)/HER2-positive metastatic breast cancer (MBC)', in Annals of oncology : official journal of the European Society for Medical Oncology, Vol. 29, pp. viii121, http://dx.doi.org/10.1093/annonc/mdy272.357

Lim E; Portman N; Alexandrou S; Haupt S; Haupt Y; Caldon E, 2017, 'Therapeutic targeting of CDK4/6 inhibitor resistant breast cancer', in CANCER RESEARCH, AMER ASSOC CANCER RESEARCH, TX, San Antonio, Vol. 78, presented at San Antonio Breast Cancer Symposium, TX, San Antonio, 05 December 2017 - 09 December 2017

Anderson RL; Swarbrick A; Johnstone R; Chua B; Gill A; Saunders C; Lakhani S; Lim E; Loi S; O'Toole SA; Khanna KK; Devereux L; Harvey K; Reed AM, 2017, 'Brocade: The National Breast Cancer Foundation Repository of Primary Tumours and Metastases from Breast Cancer Patients', in ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, WILEY, Vol. 13, pp. 110 - 111, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000413954500136&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Lin FP-Y; Martin C; Kocbek S; Joshua AM; Dear RF-G; Lim E; Chantrill LA; Chin VT; Epstein RJ, 2017, 'Identifying determinants of quality of life in patients undergoing systemic therapy for solid tumors.', in JOURNAL OF CLINICAL ONCOLOGY, AMER SOC CLINICAL ONCOLOGY, IL, Chicago, Vol. 35, presented at 53rd Annual Clinical Science Meeting of the American-Society-of-Clinical-Oncology (ASCO) / Symposium on Old Targets, New Drugs - Her2 and MET, IL, Chicago, 02 June 2017 - 07 June 2017, http://dx.doi.org/10.1200/JCO.2017.35.15_suppl.6596

Back to profile page